|
|
|
Antimicrobial Agents and Chemotherapy, September 2004, p . 3332-3337, Vol . 48, No . 9 Plasmid-Encoded Multidrug Efflux Pump Conferring Resistance to Olaquindox in Escherichia coli
Lars Hestbjerg Hansen,* Elsebetta Johannesen, Mette Burmølle, Anders Hay Sørensen, Department of Microbiology, University of Copenhagen, Copenhagen, Denmark Received 3 March 2004/ Returned for modification 14 April 2004/ Accepted 17 May 2004
We describe here the isolation, subcloning, and sequencing of the plasmid-borne resistance determinant for OQX . Furthermore, a mode of action for this resistance mechanism is proposed and validated .
Antibiotics were added to both liquid and solid media for plasmid selection at the following concentrations unless stated otherwise: AMP, 100 µg/ml; kanamycin (KAN), 50 µg/ml; tetracycline (TET), 10 µg/ml; and OQX, 100 µg/ml . Stock solutions of AMP and KAN were prepared as 10 mg/ml in water . Stock solutions of TET were prepared as 10 mg/ml in 50% (wt/vol) ethanol, and CHL solutions were prepared as 10 µg/ml in methanol . Stock solutions of OQX were prepared as 10 mg/ml dissolved in 5 M NaOH . After the addition of OQX, the media were neutralized by using an equal amount of 5 M HCl . AMP, CHL, KAN, and TET were purchased from Sigma Chemical Co . (St . Louis, Mo.), and OQX was purchased from CNS Biomedicals, Inc . (Aurora, Ohio) . All enzymes were purchased from New England Biolabs (Beverly, Mass.) unless otherwise stated . All DNA manipulations and preparations were carried out by standard methods (15) unless described otherwise in the text .
Subcloning and sequencing of the OQX resistance determinants.
Based on preliminary restriction enzyme mapping and partial sequencing, pOLA52 was digested with ApaLI . Fragments were ligated into the unique ApaLI site of pLOW2 (9), transformed into E . coli N43, and plated onto LB plates containing 64 µg of OQX/ml . Resistant colonies contained a 6-kb ApaLI insert, resulting in a plasmid named pLOW2::oqxAB . This fragment was subsequently sequenced . Plasmid DNA (pLOW2::oqxAB) was fragmented by sonication for 3 s and treated with Klenow and mung bean nuclease to produce blunt ends . DNA was then separated by gel electrophoresis, and DNA fragments of 1 to 3 kb were extracted by using a QIAEXII gel extraction kit (Qiagen, Inc., Valencia, Calif.) . The fragmented DNA was then ligated to a SmaI-digested pUC18 vector (12) and transformed into competent E . coli DH5 The sequencing PCR was performed with 0.3 µg of plasmid DNA as a template in 10-µl sequencing reactions containing 5 pmol of primer and sequencing mix (DYEnamic ET dye terminator cycle sequencing kit [MegaBACE]) as described by the manufacturer (Nycomed Amersham, Plc., Buckinghamshire, England) . The sequencing primers used were M13 Forward (20; 5'-GTAAAACGACGGCCAG-3') and M13 Reverse (5'-CAGGAAACAGCTATGAC-3') . Sequencing reactions were purified by using Sephadex, and sequencing was performed by using the MegaBACE 1000 sequencer (Molecular Dynamics, Sunnyvale, Calif.) . Sequences were subsequently analyzed and assembled by using Sequencher 3.0 software (GCC, Ann Arbor, Mich.) . DNA sequences were exported to DNAstrider 1.1 (Ch . Marck and C.E.A, Cedex, France) and open reading frames (ORFs) were converted into protein sequences . Both DNA and protein sequences were then examined for homology by using the National Center for Biotechnology Information's basic local alignment search tool (BLAST 2.0) (2) in January 2004 . The OqxA and OqxB sequences were next aligned to related proteins by using CLUSTAL W 1.8 (http://searchlauncher.bcm.tmc.edu.multi-align/multi-align.html) . Finally, a graphic output of the aligned sequences was created by using BOXSHADE 3.21 (http://www.ch.embnet.org/software/BOX_form.html) . The transmembrane hidden Markov model prediction server was used to predict the structure and number of transmembrane helices in the OqxB protein (16) . RT-PCR analysis of oqxAB operon. Total RNA was extracted from 1.5 ml of overnight culture of E . coli N43 and N43/pOLA52 by use of High-Pure RNA isolation kit (Roche Diagnostics, Mannheim, Germany) . From these extractions, 14 µg of RNA was used as templates in two separate reverse transcriptase (RT) reactions (42°C for 50 min, followed by 95°C for 2 min) at total volumes of 20 µl . The RT components were purchased from Roche Diagnostics (Mannheim, Germany) . The primer used in RT reactions was oqxB-reverse (5'-GGGAGAACAGATGCACCA-3') . Next, 0.5 µl of RT reaction product was used in 50-µl PCRs (DyNAzyme EXT for High Performance PCR; FINNZYMES, Espoo, Finland) . Control PCRs were made with the total RNA preparations from both strains, without performing the RT step, to verify that the RNA was DNA free . Equal amounts of total RNA were used in all PCRs . The primers used were oqxA-forward (5'-CGCGTCCAGCGATAATCA-3') and oqxB-reverse . PCR products were visualized by agarose gel electrophoresis (1.2% agarose gel) . Resistance tests. Plasmids pLOW2, pLOW2::oqxAB, and pOLA52 were transformed into E . coli N43 . Subsequently, overnight (O/N) LB broth cultures of E . coli N43, N43/pLOW2, N43/pLOW2::oqxAB, and N43/pOLA52 were diluted 200-fold in 5 ml of LB broth containing 0, 2, 4, 8, 16, 32, 64, 128, or 256 µg of OQX/ml and grown at 37°C O/N . Bacterial growth was measured as the optical densities at 600 nm (OD600s) after incubation . The MIC was defined as the lowest concentration investigated to have an inhibitory effect of the OD600 of at least 90% . Similarly, a resistance test was performed with N43/pLOW2 and N43/pLOW2::oqxAB with AMP and CHL at the following concentrations: 0, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, and 256 µg/ml . Energy-dependent drug uptake and efflux. O/N cultures of E . coli N43/pLOW2 and N43/pLOW2::oqxAB were diluted 100-fold in fresh prewarmed LB broth and shaken at 37°C . When OD600 reached 0.8, cells were washed twice in M9 medium (15) containing 0.2% glucose and 2.5 µg of thiamine/ml . Next, 2.5 ml of cells with an OD600 adjusted to 0.5, were placed in a cuvette . Then, 5 µM ethidium bromide was added at room temperature and fluorescence was continuously measured on a Perkin-Elmer LS 50B luminescence spectrometer (Perkin-Elmer, Beaconsfield, England) . Excitation and emission wavelengths were set at 500 and 580 nm, respectively . After 9 min, 40 µM carbonyl cyanide m-chlorophenylhydrazone (CCCP) was added to disrupt the proton gradient in the cells (13) . Another aliquot of the cells were washed in M9 medium containing 40 µM CCCP and 5 µM ethidium bromide . Cells were depleted of nutrients and allowed to take up ethidium bromide for 1 h at 37°C . Then, cells were washed twice in M9 media containing ethidium bromide only and incubated in a cuvette (OD600 = 0.5) at room temperature . After 5 min, glucose (0.2%) and thiamine (2.5 µg/ml) was added to supplement the cells with energy . Again, fluorescence was continuously measured on a LS 50B luminescence spectrometer . TolC requirements of the OqxAB pump for expression in E . coli. Plasmids pOLA52 was transformed into E . coli strains N43 and N43tolC::Tn10 resulting in a total of two plasmid containing strains and the two parent strains (Table 1) . Then, O/N cultures of the four strains were diluted 200-fold into 5 ml of preheated LB medium containing various concentrations of OQX as described above . The OD600 was measured after incubation as described above .
We also investigated whether the suspected multidrug resistance pump was responsible for the AMP and CHL resistances reported earlier (17) . The strains N43/pLOW2, N43/pLOW2::oqxAB, and N43/pOLA52 showed MICs of 2 µg of CHL/ml, 256 µg of CHL/ml, and 128 µg of CHL/ml, respectively (Table 1) . The twofold difference in CHL MICs between N43/pLOW2::oqxAB and N43/pOLA52 (256 and 128 µg of CHL/ml) could be due to a difference in plasmid copy number . Thus, the OqxAB pump not only confers resistance to OQX but also high (>64 µg/ml) resistance to CHL . The same AMP MICs (2 µg/ml) (Table 1) were seen with N43, N43/pLOW2, and N43/pLOW2::oqxAB, indicating that the previously observed AMP resistance originates from other determinants on pOLA52 . H+-driven ethidium efflux. Since the DNA sequence of the subcloned DNA suggested the presence of an RND family multidrug efflux pump, we examined whether pLOW2::oqxAB encodes a H+-driven ethidium efflux pump . After the addition of the protonophoric uncoupler, CCCP, a rapid influx of ethidium bromide in both N43/pLOW2 and N43/pLOW2::oqxAB was observed, suggesting that both strains contain H+-driven ethidium bromide efflux pumps (Fig . 4, left panel) . However, N43 cells containing the pLOW2::oqxAB plasmid contained a much lower intracellular ethidium bromide concentration and thereby an increased ethidium efflux ability than N43/pLOW2 before addition of CCCP . The ethidium levels reached the same concentration in both strains after the uncoupling of the H+ gradient by adding CCCP (Fig . 4, left panel) .
TolC dependency. Table 1 clearly shows an increase in resistance to OQX in the N43/pOLA52 strain . When N43/pOLA52 is compared to N43tolC::Tn10/pOLA52, it was observed that N43tolC::Tn10/pOLA52, which does not have a functioning TolC protein, demonstrates much less resistance . Therefore, the OQX resistance plasmid pOLA52 is dependent on a host-encoded outer membrane protein (OMP), such as TolC, to confer high OQX resistance . The two plasmid-free strains have the same very low level of resistance . Another interesting observation was that N43tolC::Tn10/pOLA52 evidently is significantly more tolerant to OQX than the two strains without the plasmid .
In all other reported cases, except a recent publication by Tauch et al . (20), genes encoding bacterial multidrug efflux have been associated with the chromosomes of their respective host organisms (1, 6, 11, 18, 22) . This minimizes the risk of proliferation of these systems by conjugative or mobilized horizontal plasmid transfer . The exchanges of genetic material between microorganisms have been proposed as a major contributor in the rapid evolution of microorganisms resistant to antibiotics (21) . In the present study we have identified a multidrug efflux pump encoded on a conjugative plasmid . The fact that multidrug efflux pumps are now appearing on conjugative plasmids raises doubt in our conception of "safe to use" drugs . Here we see a bacterial multidrug resistance pump, potentially spreading itself around on conjugative plasmids, probably as a consequence of the use of OQX as a growth promoter . In fact, it can be concluded that the use of antimicrobial agents such as OQX in animal husbandry potentially selects for multidrug resistance . The two findings of plasmid-borne RND family multidrug efflux pumps could be an emerging resistance problem of disturbing proportions . In this case, the gene system, which encodes resistance to OQX, also gives high resistance to the antibiotic CHL with some therapeutic use . Further investigations on the resistance spectrum encoded by the oqxAB system will reveal how broad a range of antibiotics is susceptible to the action of this pump .
Sequence data shows three ORFs encoding putative proteins, two of which show strong homology to several multidrug efflux pumps . The protein alignments in Fig . 2 shows that the OqxA and OqxB sequences consist of several conserved blocks of amino acids similar to other verified and putative RND family proteins . The putative OqxB protein contains 12 transmembrane
The expression of the oqxA and oqxB genes was demonstrated by RT-PCR analysis, which also indicates that the two genes oqxA and oqxB are contained in the same operon . This was expected due to the fact that the two genes are separated by only 24 bp, as described earlier . The possibility that the PCR product obtained in the N43/pOLA52-RT-reaction could be based on a small amount of plasmid DNA present in the RNA extraction can be excluded, since the PCR containing total RNA of N43/pOLA52 as a template did not result in product formation . Verification of an efflux system encoded by the oqxAB operon was provided by the ethidium uptake/efflux study (Fig . 4) . These results show that the oqxAB genes on pLOW2::oqxAB do indeed confer H+-driven ethidium bromide efflux ability to the cells . This supports the assumption that oqxAB genes do encode a multidrug efflux pump since ethidium efflux is a common feature among the efflux systems described earlier (13) . Additional support for a multidrug efflux pump of the RND family was seen in the TolC test . RND family efflux pumps all require an OMP such as OprM (7, 13) or TolC (5, 13) to function . Specifically, Mine et al . showed that a similar efflux pump from P . aeruginosa, the MexXY pump, required the TolC protein to function in E . coli (13) . We have tested the TolC requirement of the OqxAB pump in the same strains N43 (TolC+) and N43tolC::Tn10 (TolC) . As shown in Table 1, the OqxAB system requires TolC to function fully in E . coli N43 . However, it can also be seen that, even in the TolC strain, plasmid pOLA52 confers an increase in OQX MIC from 8 to 16 µg/ml . The reason for this is unknown . Either the low-level resistance caused by pOLA52 is due to the OqxAB pump functioning at low efficiency without TolC as an OMP, or another protein, transcribed from pOLA52 or the host chromosome, compensates for the lack of TolC in the N43tolC::Tn10 strain . Since the pOLA52 plasmid was isolated from E . coli, which usually provides the TolC OMP, it could be argued that it could confer resistance without encoding the OMP . Thus far we have not been able to identify an OMP candidate from pOLA52 .
This study was partly funded by a grant from the Danish Natural Science Research Council (SNF 24-56998) .
What Is Biofilm?,
What Is Botulism?,
What Is Environmental Microbiology?,
What Is Water Purification?,
What Is Genetics?,
c,
Microorganisms,
c,
Bacterium,
c,
Bacteria,
n,
Microorganism,
o,
Microbes,
i,
Prokaryotes,
e,
Biofilms,
s,
Gram negative,
n,
Paenibacilli,
i,
Candida albicans,
n,
Escherichia coli,
c,
Salmonella,
n,
Microorganisms,
n,
Escherichia coli,
a,
Microorganism,
a,
Proteus,
r,
Bacillus,
a,
Vibriosis,
s,
Escherichia coli,
n,
Antimicrobial,
e,
Antibiotic treatment,
a,
Antibiotic treatment,
a,
Bacillus,
a,
Streptococci,
s,
Haemophilus,
o,
Microflora
|
© 2005
Transgalactic Ltd (manufacturer of Bioscreen C software) |
Privacy Statement | P.O. Box
1393, 00101 Helsinki, Finland,
Last modified: May 25, 2005
| ||||||